Company Profile
Knight Therapeutics focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma.
Its portfolio also includes Pemazyre for metastatic cholangiocarcinoma, Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting, Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy, Tavalisse for the treatment of chronic immune thrombocytopenia, Trelstar for advanced prostate cancer, Vidaza for myelodysplastic syndrome, Abraxane for metastatic pancreatic cancer, Halaven for metastatic breast cancer and soft tissue sarcoma, Lenvima for advanced renal cell cancer, Zyvalix for metastatic prostate cancer, Karfib for relapsed or refractory multiple myeloma, Leprid for advanced prostate cancer, Bapoci for brest cancer, Xetrane for multiple myeloma, Rembre for chronic myeloid leukemia, Imvexxy for moderate to severe dyspareunia, Bijuva for moderate to severe vasomotor symptoms, IPX203 for Parkinson's disease, Qelbree for attention-deficit hyperactivity disorder, Jornay PM for attention-deficit hyperactivity disorder, and Crexon for Parkinson's disease, as well as Salofalk for ulcerative colitis.
Its portfolio also includes Ursofalk for biliary cirrhosis, Fibridoner for idiopathic pulmonary fibrosis, Ibsrela for IBS-C, and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease.
It also offers Niktimvo. Its portfolio also includes Zynyz, Gemtesa, Orgovyx, Myfembree, Onicit, Jornay PM and Crexont capsules, and Palbocil and Bapocil for treatment of patients with hormone receptor positive Finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.